LDS/Medical Tests/IgA Subclasses

IgA Subclasses

Immunoglobulins (antibodies) are glycoproteins produced by plasma cells, essential for humoral immune responses. There are five primary immunoglobulin isotypes: IgG, IgM, IgA, IgE, and IgD. Among these, IgA constitutes approximately 10–15% of total immunoglobulins and is crucial for mucosal immunity. IgA occurs in two subclasses: IgA1 and IgA2, differing structurally and functionally.

IgA1 is the predominant subclass in systemic circulation, accounting for approximately 80% of total IgA. It is instrumental in systemic immune responses by binding antigens, forming immune complexes, and activating the alternative complement pathway. However, IgA1 has an extended hinge region, making it vulnerable to bacterial proteases. In contrast, IgA2 is predominantly found in mucosal secretions such as saliva, tears, colostrum, and gastrointestinal secretions. The shorter hinge region of IgA2 confers resistance against proteolytic cleavage by microbial enzymes, thereby enhancing mucosal protection against pathogens.

Abnormal IgA subclass levels are associated with various clinical conditions. Selective IgA deficiency (sIgAD) is characterized by low or absent IgA levels with normal IgG and IgM concentrations, predisposing individuals to recurrent infections, autoimmune conditions, and allergic reactions (including anaphylactic transfusion reactions). A general decline in immunoglobulins, including IgA, is observed in Common Variable Immunodeficiency (CVID).

Elevated levels of IgA1-containing immune complexes contribute to IgA nephropathy, a renal disorder characterized by hematuria, proteinuria, and progressive renal impairment. Autoantibodies of the IgA type are associated with gastrointestinal disorders such as celiac disease and inflammatory bowel disease (IBD).

Measurement of IgA subclasses is beneficial for differential diagnosis, disease classification, and monitoring related autoimmune, immunodeficiency, and proliferative disorders.

  • Diagnosis and assessment of selective IgA deficiency (sIgAD)
  • As an aid in the diagnosis and monitoring of IgA nephropathy
  • Differential diagnosis and evaluation of gastrointestinal autoimmune diseases, including celiac disease and inflammatory bowel disease (IBD)
  • Identification and monitoring of monoclonal gammopathies involving IgA (e.g., IgA multiple myeloma and IgA-MGUS)

Lower levels of IgA2 with normal IgA1:

  • Indicates selective IgA2 deficiency, increasing susceptibility to recurrent mucosal and disseminated infections.

Higher IgA2 levels with normal IgA1:

  • Suggestive of monoclonal proliferation of plasma cells producing monoclonal IgA2 (such as IgA multiple myeloma or MGUS-IgA).

Increased total IgA levels:

  • Commonly observed in inflammatory conditions, chronic infections, allergies, and autoimmune diseases.

Decreased total IgA levels:

  • Suggestive of selective IgA deficiency or common variable immunodeficiency (CVID).
Total IgA – Age Group Reference Range
1–3.9 years 5–194 mg/dL
4–6.9 years 16–210 mg/dL
7–9.9 years 27–227 mg/dL
10–11.9 years 35–241 mg/dL
12–13.9 years 43–252 mg/dL
14–15.9 years 50–263 mg/dL
16–17.9 years 57–274 mg/dL
≥18 years 85–499 mg/dL

 

IgA1 – Age Group Reference Range
1–3.9 years 6–163 mg/dL
4–6.9 years 16–186 mg/dL
7–9.9 years 26–209 mg/dL
10–11.9 years 34–228 mg/dL
12–13.9 years 40–243 mg/dL
14–15.9 years 46–259 mg/dL
16–17.9 years 53–274 mg/dL
≥18 years 76–328 mg/dL

 

IgA2 – Age Group Reference Range
1–3.9 years <0.5–12.4 mg/dL
4–6.9 years <0.5–25.7 mg/dL
7–9.9 years 1.5–38.9 mg/dL
10–11.9 years 2.9–49.9 mg/dL
12–13.9 years 4.0–58.7 mg/dL
14–15.9 years 5.2–67.5 mg/dL
16–17.9 years 6.3–76.3 mg/dL
≥18 years 6.9–114.3 mg/dL
Quantitative measurement via Immunoturbidimetry.

Serum (SST tube).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
  • Frozen: 30 days
Basic metabolic panel, immune complex panel, NK cytotoxicity profile, respiratory pathogen panel, urinary albumin-to-creatinine ratio, urinalysis, complement component C3 and C4, glomerular basement membrane antibodies (anti-GBM), protein electrophoresis (serum and urine), celiac disease serology (anti-tTG, anti-endomysial antibodies), and fecal calprotectin (IBD marker).
1 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login